Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) EBIT Margin (2020 - 2025)

Historic EBIT Margin for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to 9.05%.

  • Xeris Biopharma Holdings' EBIT Margin rose 328100.0% to 9.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.68%, marking a year-over-year increase of 277900.0%. This contributed to the annual value of 16.57% for FY2024, which is 102800.0% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' EBIT Margin stood at 9.05%, which was up 328100.0% from 6.27% recorded in Q2 2025.
  • Xeris Biopharma Holdings' EBIT Margin's 5-year high stood at 9.05% during Q3 2025, with a 5-year trough of 289.55% in Q2 2021.
  • Its 5-year average for EBIT Margin is 75.37%, with a median of 40.0% in 2023.
  • Per our database at Business Quant, Xeris Biopharma Holdings' EBIT Margin tumbled by -740800bps in 2021 and then soared by 2148000bps in 2022.
  • Over the past 5 years, Xeris Biopharma Holdings' EBIT Margin (Quarter) stood at 225.26% in 2021, then skyrocketed by 80bps to 45.77% in 2022, then skyrocketed by 52bps to 22.17% in 2023, then surged by 113bps to 2.79% in 2024, then skyrocketed by 224bps to 9.05% in 2025.
  • Its EBIT Margin was 9.05% in Q3 2025, compared to 6.27% in Q2 2025 and 5.14% in Q1 2025.